share_log
Breakings ·  Sep 19 02:04
Biogen Exec Says if FDA's Review for Subcutaneous Leqembi Is Expedited Approval Could Come After 8 Months From Submission Vs 12 Months
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment